Clinical Trials

임상시험 트래커

국내사는 전체 임상 이력, 글로벌 메이저는 진행 중 파이프라인을 추적합니다. ClinicalTrials.gov API v2에서 6시간 주기로 수집합니다.

7,293 trials30 companiesClinicalTrials.gov ↗

Photo Jan Folwarczny / Unsplash

19 results

1/2상모집 중· Advanced Solid Tumor Cancer
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
리드: 바이오엔테크
상세 →NCT07455734
1/2상모집 중· Advanced Renal Cell Carcinoma (RCC)
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
리드: BMS · 협력: 바이오엔테크
상세 →NCT07293351
1/2상모집 중· Hepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
리드: BMS · 협력: 바이오엔테크
상세 →NCT07291076
1/2상모집 중· Advanced Solid Cancers
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
리드: 바이오엔테크
상세 →NCT07186842
1/2상모집 중· Non-small Cell Lung Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
리드: 바이오엔테크
상세 →NCT07111520
1/2상모집 중· Advanced Solid Tumor
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
리드: 바이오엔테크
상세 →NCT07147348
1/2상모집 중· Advanced Solid Tumor
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
리드: 바이오엔테크
상세 →NCT07070232
1/2상모집 중· Metastatic Colorectal Cancer
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
리드: 바이오엔테크
상세 →NCT07079631
1/2상모집 중· Advanced Lung Cancer
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
리드: 바이오엔테크
상세 →NCT06892548
1/2상모집 중· Locally Advanced Breast Cancer
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
리드: 바이오엔테크
상세 →NCT06827236
1/2상모집 중· Advanced Solid Tumor
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
리드: 바이오엔테크
상세 →NCT06750185
1/2상모집 예정· HCC
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
협력: 바이오엔테크
상세 →NCT06584071
1/2상모집 중· Advanced Solid Tumors
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
협력: 바이오엔테크
상세 →NCT05914116
1/2상모집 중단 (진행 중)· Tuberculosis
Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in BCG Vaccinated Volunteers
리드: 바이오엔테크
상세 →NCT05547464
1/2상모집 중단 (진행 중)· Advanced Solid Tumor
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
협력: 바이오엔테크
상세 →NCT05438329
1/2상모집 중단 (진행 중)· TNBC
A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC
협력: 바이오엔테크
상세 →NCT05918133
1/2상모집 중· HER2-positive Advanced Solid Tumor
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
협력: 바이오엔테크
상세 →NCT05150691
1/2상모집 중· Malignant Neoplasm
PM8002 in the Treatment of Patients With Advanced Solid Tumors
협력: 바이오엔테크
상세 →NCT05918445
1/2상모집 중단 (진행 중)· Malignant Solid Tumor
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
협력: 바이오엔테크
상세 →NCT04083599

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.